B.Riley Downgrades Madrigal Pharmaceuticals (MDGL) to Sell
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $519.09 -3.9%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
B.Riley analyst Mayank Mamtani downgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Neutral to Sell with a price target of $155.00.
For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.
Shares of Madrigal Pharmaceuticals closed at $236.54 yesterday.
You May Also Be Interested In
- GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
- RBC Capital Downgrades Coty Inc. (COTY) to Sector Perform
- UBS Downgrades Merck (MRK) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
